$9.47
0.9010.5%
最終更新: Oct 1, 6:24 AM
$9.32
0.758.75%
Benzinga
Benzinga
Benzinga
木曜日, 10 01
Benzinga
© 2026 Benzinga | All Rights Reserved
Capricor Therapeutics (CAPR) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-0.58 | $-0.54 | $-0.53 | $-0.54 |
| Actual | $-0.70 | $-0.59 | $-0.62 | $-0.54 |
| Surprise | -20.7% | -9.26% | -17.0% | 0.00% |
| Revenue | ||||
| Estimate | — | $25.2M | $1.7M | $1.2M |
| Actual | $0 | $0 | $0 | $0 |
| Surprise | — | -100.0% | -100.0% | -100.0% |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $-0.46 | $-0.05 | $-0.48 | $-0.36 |
| Revenue | ||||
| Consensus | $10.4M | $22.9M | — | — |
| 会計四半期 | 報告日 | 実質EPS | 推定EPS | 驚き ％ |
|---|---|---|---|---|
| Q2 | Aug 13, 2026 | $-0.70 | $-0.58 | -20.7 % |
| Q1 | May 12, 2026 | $-0.59 | $-0.54 | -9.26 % |
| Q4 | Mar 12, 2026 | $-0.62 | $-0.53 | -17.0 % |
| Q3 | Nov 10, 2025 | $-0.54 | $-0.54 | 0.00 % |
| 会計四半期 | 報告日 | 実際の収益 | 推定収益 | 驚き ％ |
|---|---|---|---|---|
| Q1 | May 12, 2026 | $0 | $25.20M | -100.0 % |
| Q4 | Mar 12, 2026 | $0 | $1.68M | -100.0 % |
| Q3 | Nov 10, 2025 | $0 | $1.25M | -100.0 % |
| Q2 | Aug 11, 2025 | $0 | $1.62M | -100.0 % |